These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 30999276)
1. MADD silencing enhances anti-tumor activity of TRAIL in anaplastic thyroid cancer. Saini S; Sripada L; Tulla K; Qiao G; Kunda N; Maker AV; Prabhakar BS Endocr Relat Cancer; 2019 Jun; 26(6):551-563. PubMed ID: 30999276 [TBL] [Abstract][Full Text] [Related]
2. Down-modulation of expression, or dephosphorylation, of IG20/MADD in tumor necrosis factor-related apoptosis-inducing ligand-resistant thyroid cancer cells makes them susceptible to treatment with this ligand. Li LC; Jayarama S; Pilli T; Qian L; Pacini F; Prabhakar BS Thyroid; 2013 Jan; 23(1):70-8. PubMed ID: 22998497 [TBL] [Abstract][Full Text] [Related]
3. Loss of MADD expression inhibits cellular growth and metastasis in anaplastic thyroid cancer. Saini S; Sripada L; Tulla K; Kumar P; Yue F; Kunda N; Maker AV; Prabhakar BS Cell Death Dis; 2019 Feb; 10(2):145. PubMed ID: 30760700 [TBL] [Abstract][Full Text] [Related]
4. TRAIL suppresses human breast cancer cell migration via MADD/CXCR7. Wang R; Li JC Asian Pac J Cancer Prev; 2015; 16(7):2751-6. PubMed ID: 25854358 [TBL] [Abstract][Full Text] [Related]
5. MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells. Turner A; Li LC; Pilli T; Qian L; Wiley EL; Setty S; Christov K; Ganesh L; Maker AV; Li P; Kanteti P; Das Gupta TK; Prabhakar BS PLoS One; 2013; 8(2):e56817. PubMed ID: 23457619 [TBL] [Abstract][Full Text] [Related]
6. Akt-phosphorylated mitogen-activated kinase-activating death domain protein (MADD) inhibits TRAIL-induced apoptosis by blocking Fas-associated death domain (FADD) association with death receptor 4. Li P; Jayarama S; Ganesh L; Mordi D; Carr R; Kanteti P; Hay N; Prabhakar BS J Biol Chem; 2010 Jul; 285(29):22713-22. PubMed ID: 20484047 [TBL] [Abstract][Full Text] [Related]
7. Tolfenamic acid induces apoptosis and growth inhibition in anaplastic thyroid cancer: Involvement of nonsteroidal anti-inflammatory drug-activated gene-1 expression and intracellular reactive oxygen species generation. Chang JW; Kang SU; Choi JW; Shin YS; Baek SJ; Lee SH; Kim CH Free Radic Biol Med; 2014 Feb; 67():115-30. PubMed ID: 24216474 [TBL] [Abstract][Full Text] [Related]
8. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer. Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531 [TBL] [Abstract][Full Text] [Related]
9. Knockdown of MADD and c-FLIP overcomes resistance to TRAIL-induced apoptosis in ovarian cancer cells. Li LC; Jayaram S; Ganesh L; Qian L; Rotmensch J; Maker AV; Prabhakar BS Am J Obstet Gynecol; 2011 Oct; 205(4):362.e12-25. PubMed ID: 21855847 [TBL] [Abstract][Full Text] [Related]
10. Valproic acid sensitizes TRAIL-resistant anaplastic thyroid carcinoma cells to apoptotic cell death. Cha HY; Lee BS; Kang S; Shin YS; Chang JW; Sung ES; Kim YS; Choi JW; Kim JH; Kim CH Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S716-24. PubMed ID: 23982257 [TBL] [Abstract][Full Text] [Related]
13. MADD/DENN splice variant of the IG20 gene is a negative regulator of caspase-8 activation. Knockdown enhances TRAIL-induced apoptosis of cancer cells. Mulherkar N; Prasad KV; Prabhakar BS J Biol Chem; 2007 Apr; 282(16):11715-21. PubMed ID: 17314102 [TBL] [Abstract][Full Text] [Related]
14. MADD is a downstream target of PTEN in triggering apoptosis. Jayarama S; Li LC; Ganesh L; Mardi D; Kanteti P; Hay N; Li P; Prabhakar BS J Cell Biochem; 2014 Feb; 115(2):261-70. PubMed ID: 24038283 [TBL] [Abstract][Full Text] [Related]
15. LncRNA NEAT1 enhances the resistance of anaplastic thyroid carcinoma cells to cisplatin by sponging miR‑9‑5p and regulating SPAG9 expression. Yan P; Su Z; Zhang Z; Gao T Int J Oncol; 2019 Nov; 55(5):988-1002. PubMed ID: 31485599 [TBL] [Abstract][Full Text] [Related]
16. Downregulation of Nrf2 by the combination of TRAIL and Valproic acid induces apoptotic cell death of TRAIL-resistant papillary thyroid cancer cells via suppression of Bcl-xL. Cha HY; Lee BS; Chang JW; Park JK; Han JH; Kim YS; Shin YS; Byeon HK; Kim CH Cancer Lett; 2016 Mar; 372(1):65-74. PubMed ID: 26721202 [TBL] [Abstract][Full Text] [Related]
17. Alantolactone induces concurrent apoptosis and GSDME-dependent pyroptosis of anaplastic thyroid cancer through ROS mitochondria-dependent caspase pathway. Hu Y; Wen Q; Cai Y; Liu Y; Ma W; Li Q; Song F; Guo Y; Zhu L; Ge J; Zeng Q; Wang J; Yin C; Zheng G; Ge M Phytomedicine; 2023 Jan; 108():154528. PubMed ID: 36343549 [TBL] [Abstract][Full Text] [Related]
18. MADD, a splice variant of IG20, is indispensable for MAPK activation and protection against apoptosis upon tumor necrosis factor-alpha treatment. Kurada BRVVSN; Li LC; Mulherkar N; Subramanian M; Prasad KV; Prabhakar BS J Biol Chem; 2009 May; 284(20):13533-13541. PubMed ID: 19289468 [TBL] [Abstract][Full Text] [Related]
19. MADD promotes the survival of human lung adenocarcinoma cells by inhibiting apoptosis. Bi W; Wei Y; Wu J; Sun G; Guo Y; Zhang Q; Dong L Oncol Rep; 2013 Apr; 29(4):1533-9. PubMed ID: 23443411 [TBL] [Abstract][Full Text] [Related]
20. Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death. Conticello C; Adamo L; Giuffrida R; Vicari L; Zeuner A; Eramo A; Anastasi G; Memeo L; Giuffrida D; Iannolo G; Gulisano M; De Maria R J Clin Endocrinol Metab; 2007 May; 92(5):1938-42. PubMed ID: 17327374 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]